Email
TextLatest News on Clinical Trials
Inivata announces launch of clinical trial to evaluate impact of InVisionFirst®-Lung liquid biopsy test on time to appropriate treatment in advanced lung cancer
Inivata announces launch of clinical trial to evaluate impact of InVisionFirst®-Lung liquid biopsy test on time to appropriate treatment in advanced lung cancer Prospective, interventional study sponsored by Centre Léon Bérard cancer center will compare use of...
Carrot Inc. Announces Clinical Trial Outcomes for Pivot, its Evidence-based Digital Health Solution for Smoking Cessation
Pivot increases motivation to quit and achieves quit rate of 32.4% in a study population where 66.5% of participants were not ready to quit smoking cigarettes Digital health company Carrot Inc. today announced the results of the largest clinical trial yet for Pivot®,...
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with metastatic colorectal cancer
Combination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer Companies plan indication-seeking trial WHIPPANY, N.J. and PRINCETON, N.J. and OSAKA, Japan, July 18, 2019 /PRNewswire/...
Phase 3 Trial in the Works for Novel Non-Amyloid Alzheimer’s Drug
With the latest major Phase 3 failure of Biogen and Eisai’s beta-amyloid-targeting antibody drug aducanumab, researchers are increasingly turning to other drug targets for Alzheimer’s disease. “The absence of new drug approvals since 2003 and a rapidly growing...
MyoKardia Announces HCM Program Updates: Accelerates Timing for Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights to HCM Programs from Sanofi
EXPLORER-HCM Patient Screening Closes Ahead of Schedule – Initial Results Now Anticipated in the Second Quarter of 2020 Royalty Purchase Creates Additional Economic Value for MyoKardia’s Emerging HCM Treatment Portfolio MyoKardia, Inc. (MYOK) today announced updates...
Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis
Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has completed enrollment in its phase 3 trial evaluating arimoclomol for the treatment of Amyotrophic...
CVS Health Announces Start of Clinical Trial for New Home Hemodialysis Device
HemoCare™ Hemodialysis System designed for home dialysis to enable patients to benefit from longer treatment as compared to in-center treatments Represents next step in company-wide strategy to help improve kidney disease diagnosis and management CVS Health...
Marker Therapeutics to Host Conference Call and Webcast to Review Interim Results from Phase 1/2 Clinical Trial with its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma
Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced it will host...
Halozyme Announces First Clinical Dosing In argenx’s Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has dosed the first subject in a phase 1 clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics...
Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative
Long acting Relaxin is powered by Ambrx technology SAN DIEGO, July 16, 2019 /PRNewswire/ -- Ambrx Inc. today announced that Bristol-Myers Squibb Company ("BMS") has initiated a phase I clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of...
Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD
Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and...
Capricor Therapeutics and Parents Project Muscular Dystrophy to Host Webinar to Discuss Interim Analysis of the HOPE-2 Clinical Trial to Treat Patients with Duchenne Muscular Dystrophy
LOS ANGELES, July 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) announced positive results from its interim analysis in the HOPE-2 Trial on Monday. The public is invited to join Parent Project...
Axial Biotherapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AB-2004 for Treatment of Gastrointestinal Dysfunction and Associated Behavioral Symptoms of Autism Spectrum Disorder
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced the dosing of the first patient in its Phase 1b/2a clinical trial of AB-2004....
Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF
multilang-release Study expands potential clinical indications for lead compound Trial fully funded via a grant from the United States National Institutes of Health ARCHAMPS, France, July 17, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris &...
GSK’s Zejula meets primary endpoint in phase 3 ovarian cancer trial
GlaxoSmithKline (GSK) said that a phase 3 trial evaluating its polymerase (PARP) inhibitor Zejula (niraparib) as a maintenance therapy for first-line ovarian cancer following platinum-based chemotherapy, has met its primary endpoint. Image: GSK’s Zejula...
Mallinckrodt Halts Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)
Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced that it is permanently discontinuing its Phase 2B study designed to assess the efficacy and safety of Acthar® Gel (repository corticotropin injection) as an...
Elios Therapeutics Announces Positive Top-Line Data from Phase IIb Study Evaluating TLPLDC, a Personalized Therapeutic Cancer Vaccine, in Patients with High-Risk Melanoma
~ Results Show Treatment with the TLPLDC Vaccine Significantly Reduced the Risk of Disease Recurrence by 50 Percent Compared to Placebo in Patients with Stage III and IV Resected Melanoma Who Completed the Primary Vaccine Series ~~ TLPLDC Continues to Demonstrate a...
Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD
Full enrollment expected to occur in calendar Q4 2019 Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of...
Arbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506, an Oral Capsid Inhibitor in Development for People with Chronic Hepatitis B
Results demonstrate that AB-506 is a potent capsid inhibitor Phase 1a/1b clinical trial to continue with the enrollment of further cohorts Conference call and webcast scheduled today at 4:45 pm ET Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading...
SurgiMab Advances SGM-101, a Novel Fluorescent Tumor-specific Antibody, Into Pivotal Phase 3 Clinical Trial to Improve Surgical Outcomes in Colorectal Cancer Patients
SGM-101 has the potential to be the first tumor-targeted fluorescent probe to be marketed for fluorescence-guided surgery (FGS) SurgiMab, a late-stage biotechnology company pioneering a new antibody-based fluorescence-guided approach designed to improve cancer surgery...